dabrafenib

Novartis Nets Tumor-Agnostic Approval for Tafinlar-Mekinist Combo

Novartis Q1 Revenues Grow 1 Percent Amid Organizational Restructuring, Shifting Growth Drivers

NCI-MATCH Umbrella Trial Adds Arm for LAG-3 Expressing, Mismatch Repair Deficient Cancers

Novartis Q4 Revenues Increase 4 Percent Bolstered by Oncology Drug Sales

Foundation Medicine Test Nabs FDA Approval as CDx for BRAF Inhibitor Therapeutics for Melanoma

Novartis Q2 Revenues Grow 14 Percent

Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases

AACR Studies in BRAF-Mutated Melanoma Show Benefit of Combo Treatment, Continuous Dosing Strategies

Colorectal Cancers Dial up Mutability in Response to Targeted Treatments

Thermo Fisher Next-Gen Sequencing Panel Wins FDA Approval as Companion Test